Evidence map›Paper›PMID 42500891›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

KMT5a-Mediated IRF3 Stabilization Enhances Macrophage Chemotaxis and Renal Fibrosis Progression.

Mingzheng Yang, Ping Xia, Juan Liu, Hongli Yang, Yunjia Jiang, Minggang Wei

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mingzheng YangDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Ping XiaDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.ORCID https://orcid.org/0000-0001-7852-6764
Juan LiuDepartment of Nephrology, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, People's Republic of China.
Hongli YangDepartment of Nephrology, Nantong First People's Hospital, Nantong, People's Republic of China.
Yunjia JiangDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Minggang WeiDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.ORCID https://orcid.org/0009-0006-9153-1668

Funding

Foundation Research Project of Jiangsu Province CYTF2024042Foundation Research Project of Jiangsu Province PDJH2024040Jiangsu Provincial Medical Innovation Center CXZX202233Jiangsu Provincial Medical Innovation Center SLJ0330Suzhou Municipal Health Commission () MSXM2024006
6 · The paper itself

Abstract

While the histone lysine methyltransferase (KMT) family responsible for posttranslational modification has been reported to regulate multiple diseases progression like tumor and cardiovascular disease, its role in renal fibrosis progression is not completely understood. Here, via TGF-β-treated HK-2 cells and an in vivo unilateral ureteral obstruction mice model, the histone lysine methyltransferase family was screened and the upregulated expression of KMT5a was identified in these renal fibrosis models. Interference assays using lentivirus transfection in HK-2 cells and transgenic mice displayed that KMT5a silencing in HK-2 cells impeded macrophage chemotaxis. Moreover, in vivo, transgenic KMT5a knockout inhibited macrophage infiltration, which contributed to the suppression of renal fibrosis progression. Mechanistically, by immunoprecipitation assays and mass spectrometry, we discovered that KMT5a could interact with and stabilize the transcription factor IRF3 to regulate macrophage chemotaxis and infiltration in renal tissues, which accelerated renal fibrosis progression. Notably, we confirmed that a small molecular inhibitor of KMT5a, UNC0379, reduced IRF3 protein levels and macrophage chemotaxis, thus suppressing renal fibrosis, in vitro and in vivo. Therefore, this study presented KMT5a as a mediator of renal fibrosis progression, an effect that was reversed by the KMT5a inhibitor UNC0379, which provided evidence of a novel target and potential drug for inhibiting renal fibrosis progression.

Indexed as

ChemotaxisHistone-Lysine N-MethyltransferaseKidneyKidney DiseasesMacrophagesAnimalsCell LineDisease ProgressionFibrosisHumansInterferon Regulatory Factor-3Interferon Regulatory FactorsMaleMiceMice, Inbred C57BLMice, KnockoutHistone-Lysine N-MethyltransferaseInterferon Regulatory Factor-3Interferon Regulatory FactorsIrf3 protein, mouseIRF3KMT5amacrophagerenal fibrosisUNC0379

Identifiers

PMID42500891
PMCPMC13401259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.